2693MO COTESARC: A multicentre, open-label, phase I-II evaluating the combination of MEK and PDL-1 inhibitors in patients with advanced soft tissue sarcoma (STS)
A. Dufresne, M. Brahmi, Claire Cropet, R. Bahleda, Sarah Watson, P. Pautier, I.L. Ray-Coquard, Isabelle Aerts, Axel Le Cesne, Anne Sophie Defachelles, F. Duffaud, G. Garin, M. Bernardin, Cécile Guichard, Laurie Tonon, Cyril Dégletagne, Bertrand Dubois, David Pérol, Jean Yves Blay, N. Corradini (2025). 2693MO COTESARC: A multicentre, open-label, phase I-II evaluating the combination of MEK and PDL-1 inhibitors in patients with advanced soft tissue sarcoma (STS). , 36, DOI: https://doi.org/10.1016/j.annonc.2025.08.3304.
